Clay B. Siegall, a scientist by training, co-founded Seattle Genetics in 1998. He has held the President, Chief Executive Officer, and the Chairman position of the company’s board to date. He holds B. Sc in Zoology from the University of Maryland and a PhD in Genetics from George Washington University.
Dr. Siegall places emphasis on cancer therapies. With his scientific innovation and the passion for helping cancer patients, he built the foundation. Before he founded Seattle Genetics, he used to work with Bristol-Myers Squibb Pharmaceutical Research Institute that operated from 1991 to 1997. He also worked for the National Cancer Institute from 1988 to 1991.
Dr. Siegall developed the antibody drug conjugates (ADCs) which have guided the company and given it its current leadership. It has also aided it in securing its approval to 2011 FDA for its first product, ADCETRIS. The drug is approved in more than 65 countries. The approval has been made possible by collaboration with Takeda Pharmaceutical Company. Seattle Genetics has advanced proprietary ADCs of the pipeline for the treatment of cancer.
Siegall has played a very significant role in the communities concerning cancer treatment. He has plans to add more personnel to help in the communities to enable more people to access the healthcare services. He is also making an effort to expand the drug pipeline using the current medications.
Clay B.Siegall is a cancer researcher. He has spent most of his years in search of a cure for cancer. He has earned a reputation for the success of his firm Seattle Genetics, which he has recently transformed to one of the most innovative biotechnology firms in the world. He is currently doing his work in collaboration with the largest pharmaceutical companies in a bid to market the products that they have already designed.
Besides being a scientist and a doctor, Dr. Siegall is also an author. He has published over 70 publications.